scPharmaceuticals Q4 2021 Earnings Report
Key Takeaways
scPharmaceuticals Inc. reported a net loss of $7.3 million for the fourth quarter of 2021 and ended the quarter with $75.5 million in cash, cash equivalents, restricted cash and investments. The company is preparing for the potential commercial launch of FUROSCIX in Q4 2022, pending FDA approval.
Completed all testing for FUROSCIX® and plan to re-submit NDA by April 15, 2022.
Commercial preparedness activities are ramping up to support the anticipated Q4 2022 launch of FUROSCIX, if approved.
Presented key FREEDOM-HF secondary endpoint data at the Cardiovascular Research Foundation Technology and Heart Failure Therapeutics Conference 2022.
Ended Q4 with cash, cash equivalents, restricted cash and investments of $75.5 million.
scPharmaceuticals
scPharmaceuticals
Forward Guidance
Based on its current operating plan, the Company forecasts its 2022 net loss to be $43 to $48 million.